Home Atlantic Therapeutics

Atlantic Therapeutics

Atlantic Therapeutics Announces FDA Clearance for Over-the-Counter Use of INNOVO®

This approval represents a major milestone that will be a key value driver for Atlantic Therapeutics.

Atlantic Therapeutics To Launch INNOVO® – Novel Therapeutic Device For Stress Urinary Incontinence

4/9/19: INNOVO was approved by the United States Food and Drug Administration on November 13, 2018, and is the first ever transcutaneous electrical stimulator cleared by the FDA, offering U.S. women a safe, clinically effective and non-invasive choice to treat stress urinary incontinence

Atlantic Therapeutics to Launch Novel Therapeutic Device For Stress Urinary Incontinence

4/3/19: INNOVO® was approved by the United States Food and Drug Administration November 13, 2018, and is the first ever transcutaneous electrical stimulator cleared by the FDA, offering U.S. women a safe, clinically effective and non-invasive choice to treat stress urinary incontinence. In its pivotal multi-center randomized controlled clinical trial, 87.2% of INNOVO® users were dry or almost dry after a 12-week treatment period, with 80% of patients experiencing improvement in just 4 weeks.